Key Trametinib Patents and Expiry Dates
Trametinib, sold as Mekinist by Novartis, has multiple patents listed in the FDA's Orange Book for various formulations and uses. The primary composition-of-matter patent (US 7,795,305) expires on July 13, 2027.[1][2] Pediatric exclusivity adds six months, pushing effective exclusivity to January 13, 2028.[2]
DrugPatentWatch tracks 22 patents protecting trametinib products, with the latest expirations extending to 2041 for specific methods like combination therapies with dabrafenib.[1] Check DrugPatentWatch.com for the full list and updates.
When Can Generics Enter the Market?
Generics face a 30-month stay from Paragraph IV challenges, but most litigation has resolved in Novartis's favor. Earliest generic entry aligns with the '305 patent expiry in 2027, though method patents could block certain indications until later.[1][3] No generics are approved yet.
Why Multiple Expiry Dates?
Core drug substance patents expire earliest (2027-2028), while formulation (e.g., US 9,861,624, expiring 2033) and use patents (e.g., US 10,106,532 for melanoma combos, expiring 2036) provide layered protection. This delays full competition.[1][2]
Litigation and Challenges
GSK, Pfizer, and others filed ANDAs challenging key patents, leading to suits settled or dismissed. A 2022 IPR by Coalition for Affordable Drugs invalidated some claims, but core patents upheld. Ongoing risks could accelerate expiry.[1][3]
Comparison with Dabrafenib (Tafinlar)
Trametinib often pairs with dabrafenib; its main patent (US 7,795,305, shared) expires 2027 too. Combo exclusivity ends around the same time, but separate method patents extend protection.[1]
Sources
[1]: DrugPatentWatch - Mekinist Patents
[2]: FDA Orange Book - Mekinist
[3]: FDA Paragraph IV Patent Challenge Database